HCPLive Network

Including Newer Biomarkers in Testing Improves Death Prediction in Chronic Kidney Disease

Though patients with chronic kidney disease (CKD) have variable risks of death, the population risk prediction tools that are currently available perform poorly. 
 
To establish more satisfactory prediction models, Adeera Levin, MD, and colleagues from the Division of Nephrology of the Department of Medicine of the University of British Columbia undertook the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) — a large, prospective cohort study that began in 2008 — and reported their findings at Kidney Week 2013, the American Society of Nephrology's annual  meeting held November 5-10, 2013, in Atlanta, GA.
 
In that study, 2,544 CKD patients referred from 25 rural, urban, academic, and non-academic centers throughout Canada underwent baseline newer biomarker (NMB) tests, which included asymmetric dimethylarginine (ADMA), high sensitivity C-reactive protein (hsCRP), interleukin 6, N-terminal pro-brain natriuretic peptide (NTproBNP), troponin I, transforming growth factor beta 1 (TGFβ1), cystatin C, and fibroblast growth factor (FGF23). The mean age of the cohort was 68 years old, while the median estimated glomerular filtration rate (eGFR) was 28ml/min/1.73m2. According to the researchers, 48% of patients had diabetes,  and 15.5% died during the 3-year follow-up.
 
Patients were followed for 3 years at 6-month intervals and annually monitored for traditional biomarkers, such as eGFR, urine albumin creatinine ratio (uACR), hemoglobin (Hgb), and phosphate and albumin. The researchers also performed the aforementioned NMB tests after collecting blood and urine samples on schedule.
 
To investigate whether including NBMs improve the prediction of death risk in CKD patients to a greater extent than conventional clinical, demographic, and laboratory predictors, the researchers compared discrimination (C statistic) and classification (NRI) of proportional hazard models based on conventional markers versus a combination of conventional and NBM markers.
 
After adjusting for base predictors, they found that the biomarker NTproBNP was the best predictor of mortality (NRI=8.9; 95% confidence interval [CI]: 3.3-17.4), followed by hsCRP (NRI=4.5; 95% CI: 1.3-9.6) and FGF23 (NRI=3.1; 95% CI: 0.4-11.4).
 
While the authors found that including NBMs in risk prediction models significantly improves the precision of death prediction in CKD patients, they noted that their approach needs to be validated with further testing.
 
The authors disclosed support from Ortho Janssen.


Further Reading
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
New research suggests that oral immunotherapy may trigger anaphylaxis in an unusually high percentage of asthmatic teenagers with high-risk food allergies who failed to adhere to their management plan.
Nine percent of top-selling packaged food products in the United States contain partially hydrogenated oils, with most of these products reporting 0 grams of trans fat per serving, according to a study published Aug. 28 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.
A 3-year study of a product meant to help patients dealing with a wide range of conditions including diabetes, hypertension, and weight loss showed positive results according to manufacturer EnteroMedics, Inc.
As national and international health agencies and other groups shift their focus during the current outbreak of the Ebola virus from treatment of those patients with the virus to preventing further large scale events, a team of researchers has reported some success in looking at how Ebola compromises an infected person’s immune system.
Asymptomatic individuals with endomysial antibodies benefit from a gluten-free diet, according to a study published in the September issue of Gastroenterology.
For many patients with chronic conditions such as rheumatoid arthritis, medication adherence is often one of the most challenging aspects of the treatment process, especially when the medications prescribed by their health care professional are prohibitively expensive. A study from Manchester University recently showed that many patients with rheumatoid arthritis are not taking some of their most critical medicines due to rising drug costs.
More Reading
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.